"Oxford Vaccine Group is leading the project to study the human immune system's response to serious bacterial infections and antibiotic resistance, targeting diseases including Streptococcus pneumoniae, Staphylococcus aureus, and E. coli. Led by Professor Sir Andrew Pollard, who ran the trials for COVID-19 vaccines, the project plans to employ so-called human challenge models - which expose human volunteers to bacteria under controlled conditions - then apply modern immunology and AI tools to pinpoint the immune responses that predict protection."
"It is set to provide research labs and computing capacity supported by Oracle, which Ellison helped found. In December 2024, the University of Oxford and the EIT launched their strategic alliance. Ellison has long voiced an interest in healthcare. During the keynote of Oracle's conference in 2022, he said: "If we're not careful... we're gonna bankrupt Western civilization unless we find a more efficient way of providing healthcare to everybody.""
A research group funded by Larry Ellison will invest £118 million to apply artificial intelligence to vaccine research in collaboration with Oxford University. The Oxford Vaccine Group will lead studies of human immune responses to serious bacterial infections and antibiotic resistance, targeting Streptococcus pneumoniae, Staphylococcus aureus, and E. coli. The project, led by Professor Sir Andrew Pollard, will use human challenge models that expose volunteers to bacteria under controlled conditions, combined with advanced immunology and AI to identify immune responses that predict protection. The Ellison Institute of Technology aims to open an Oxford campus with labs and Oracle-supported computing capacity.
Read at Theregister
Unable to calculate read time
Collection
[
|
...
]